Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| SHPG | Shire PLC Sponsored ADR | 0.06% | 176.41 | 0.4% | $129.75m | |
| PRGO | Perrigo Co. Plc | -1.53% | 72.56 | 6.8% | $98.05m | |
| MNK | Mallinckrodt Plc | -2.62% | 29.70 | 21.1% | $71.66m | |
| JAZZ | Jazz Pharmaceuticals Plc | -1.14% | 159.17 | 2.2% | $69.03m | |
| ENDP | Endo International Plc | -0.25% | 15.85 | 8.9% | $59.65m | |
| PTLA | Portola Pharmaceuticals, Inc. | -3.30% | 28.40 | 7.7% | $40.55m | |
| UTHR | United Therapeutics Corporation | 1.63% | 125.94 | 14.4% | $39.16m | |
| SAGE | SAGE Therapeutics, Inc. | 0.26% | 145.51 | 9.6% | $36.92m | |
| CTLT | Catalent Inc | 0.96% | 43.00 | 2.4% | $36.86m | |
| ICPT | Intercept Pharmaceuticals, Inc. | -1.24% | 117.30 | 18.7% | $30.73m | |
| ZGNX | Zogenix, Inc. | -0.62% | 48.50 | 11.9% | $29.86m | |
| GWPH | GW Pharmaceuticals PLC Sponsored ADR | -0.17% | 140.94 | 6.8% | $29.26m | |
| SUPN | Supernus Pharmaceuticals, Inc. | -4.27% | 46.00 | 6.2% | $27.18m | |
| MDCO | Medicines Company | -1.47% | 33.56 | 21.8% | $25.01m | |
| ICLR | ICON Plc | -1.65% | 145.27 | 4.2% | $23.83m |
Company Profile
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. Endo International was founded in 1997 and is headquartered Dublin, Ireland.